Salfen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salfen

Quick Facts

Property Description
Active ingredient Prednisolone Acetate
Form Sterile Ophthalmic Suspension (Eye drops)
Pharmacological class Glucocorticoid (Corticosteroid)
Origin Synthetic Adrenocorticoid Ester
Primary Action Powerful Anti-inflammatory Effect

Salfen: Definition, Class, and Composition

Salfen is a specialized, prescription-only medicine defined by its active component, Prednisolone Acetate, a potent, single-ingredient synthetic ester. The substance is chemically classified as a glucocorticoid, a strong subgroup of the larger corticosteroid class. Prednisolone Acetate exhibits significantly higher anti-inflammatory potency than naturally occurring hydrocortisone. This characteristic potency ensures a powerful, targeted action to manage inflammatory pathways.

The Significance of the Ophthalmic Suspension Form

The medication is formulated as a sterile ophthalmic suspension, the specific delivery vehicle for its intended use as eye drops applied topically. This preparation means the active ingredient, Prednisolone Acetate, is present as microfine, solid particles uniformly dispersed within a liquid aqueous vehicle. The suspension form is a critical differentiating feature; unlike clear solutions, the microscopic particulate nature of the corticosteroid is engineered to remain in sustained contact with the ocular surface. This unique pharmaceutical design enhances the localized therapeutic efficacy, which is paramount when treating inflammation affecting the eye's anterior segment.

Primary Function: General Anti-inflammatory Purpose

The core function of Salfen is to rapidly control acute inflammation associated with various steroid-responsive conditions. As a powerful glucocorticoid, Prednisolone Acetate works by inhibiting key components of the inflammatory cascade, including the edema, fibrin deposition, and migration of inflammatory cells. This comprehensive cellular stabilization is why the medication is used generally to achieve immediate and effective suppression of inflammation, thereby relieving the associated discomfort, redness, and swelling. Its use is generally intended for patient groups requiring a strong anti-inflammatory response to acute ocular irritation.

What side effects are possible with Salfen?

Possible Side Effects and Safety Information

Salfen, an agent of the nonsteroidal anti-inflammatory drug (NSAID) class, is associated with documented risks concerning the cardiovascular and gastrointestinal systems, which are key components of its regulatory safety profile.

Serious and Clinically Significant Adverse Reactions

Official regulatory documents highlight the potential for serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which may be fatal. This risk may increase with higher doses and prolonged use. Salfen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

There is also a risk of serious gastrointestinal (GI) adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can occur without warning symptoms and may be fatal. The risk of these events generally increases with the duration of use.

Other serious adverse reactions include hepatotoxicity, which can lead to liver failure, severe allergic/anaphylactic reactions, renal toxicity (e.g., acute renal failure, hyperkalemia), and serious skin reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Adverse Reaction Categories

Classification Examples of Reactions
System-Organ Classes Gastrointestinal disorders, Nervous System disorders (e.g., headache, dizziness, drowsiness), Cardiovascular disorders, Hepatic disorders, Renal disorders, and Skin disorders.
Common (typically ge 1%) Dyspepsia, nausea, headache, dizziness, stomach pain.

Population-Specific Safety Considerations and Restrictions

  • Contraindications: Salfen is strictly contraindicated in patients with a known hypersensitivity to the drug, a history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs, and for the treatment of peri-operative pain in the setting of CABG surgery.
  • Pregnancy: Use of Salfen is generally advised against starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus.
  • Risk Mitigation: The lowest effective dose should be used for the shortest duration necessary to mitigate the potential risk of an adverse cardiovascular event.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Salfen (prednisolone acetate ophthalmic suspension) by focusing on its minimal acute risk when used as intended. Due to the topical ophthalmic route of administration, acute overdosage is documented as unlikely to cause acute problems and is not expected to cause severe symptoms. Regulatory authorities formally state that there is no clinical experience of overdosage recorded for this specific eye drop formulation, and no severe or life-threatening manifestations are listed as resulting from acute topical overdose.

Emergency Actions and Required Care

Immediate medical attention is officially required only for the non-intended event of accidental oral ingestion.

Scenario Regulator-Mandated Action
Acute topical overdosage Acute systemic effects are unlikely; no specific emergency action is mandated.
Accidental oral ingestion Contact emergency services or a Poisons Centre immediately.

Following accidental ingestion, the supportive measures described by regulators include the procedural step of drinking fluids to dilute the product. Management of any resulting systemic effects relies on general symptomatic and supportive treatment. The official prescribing information also confirms that no specific antidote is documented as being available for the management of overdose. No specialized acute monitoring or population-specific considerations are detailed for the overdose scenario.

Therapeutic Uses of Salfen

What Salfen Treats: Main Uses and Benefits

The primary therapeutic use of Salfen (prednisolone acetate ophthalmic suspension) is applicable within clinical settings that involve steroid-responsive inflammation of the eye's anterior segment. This medication is intended for managing acute ocular inflammation. This anti-inflammatory support is generally applied in clinical settings that involve acute or disruptive symptom patterns within the eye.

It is commonly used across conditions presenting with acute episodes of deep inflammation, such as iritis, iridocyclitis, and specific non-infectious forms of keratitis. The suspension is also considered relevant when short-term symptomatic assistance is needed to manage inflammation following ophthalmic surgery (e.g., cataract extraction) or ocular trauma.

“This medication helps address symptom clusters that may become intense or disruptive, including pronounced eye pain, significant redness, and swelling that interfere with daily functioning.”

Salfen helps address symptoms related to heightened physiological activity, such as severe burning and persistent ocular irritation, offering symptomatic relief that may help patients cope more steadily with temporary functional strain. It assists with symptomatic management and supports general well-being during difficult episodes.


Quick Fact

Quick Fact: Relief for Acute Ocular Inflammation
Primary Indication: Steroid-responsive inflammation of the anterior eye (e.g., iritis, post-surgical swelling, severe allergic flares).
Main Benefit: Supports the patient by easing the overall symptom burden and discomfort.
Typical Context: Applied in scenarios where symptoms intensify and supportive relief is needed to assist with maintaining functional stability.

Eligibility and Restrictions for Use

Salfen ( Prednisolone Acetate Ophthalmic Suspension) eligibility is determined by strict official regulatory guidelines, focusing on pre-existing conditions, infections, and certain populations.

Populations Who Must Not Use Salfen (Contraindications)

Salfen is contraindicated and must not be used by individuals with:

  • Hypersensitivity: Known or suspected allergy to the active ingredient, other corticosteroids, or any excipients.
  • Active Ocular Infections: Most viral diseases (including epithelial herpes simplex keratitis, vaccinia, and varicella), fungal diseases, mycobacterial infection of the eye, and acute untreated purulent ocular infections.

Eligibility for Specific Populations

Population Group Official Eligibility Status
Adults Established use for steroid-responsive inflammation.
Pediatric Patients Varies by Region: Some regulators (US FDA) consider use established; others state safety and efficacy have not been established (e.g., UK) [Source 1.5, 3.2].
Pregnant Women Conditional Use: Only if the potential benefit justifies the potential risk to the fetus, as there are no adequate, well-controlled studies [Source 1.1].
Breastfeeding Women Not Recommended: Use is generally not recommended due to the unknown systemic absorption and potential risk to the infant [Source 1.2, 3.1].

Eligibility-Related Restrictions

Use requires great caution and frequent monitoring for patients with a history of glaucoma or a history of herpes simplex keratitis, as documented in the official labeling. Patients with known sulfite sensitivity should also exercise caution, as some formulations contain sodium bisulfite [Source 1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Salfen must be carefully managed, especially considering its active ingredients are often related to the salicylate or sulfonamide classes, which have established interaction concerns. These drug combinations can alter how one or both medicines work, potentially increasing the risk of side effects or reducing the effectiveness of therapy.

Clinically significant interactions may occur with:

  • Blood Thinners (Anticoagulants): Salfen may enhance the effect of anticoagulants such as warfarin, significantly increasing the risk of bleeding or hemorrhage due to its effect on blood clotting function.
  • Other Pain Relievers: Combining Salfen with other nonsteroidal anti-inflammatory drugs (NSAIDs) or other salicylates may increase the risk of gastrointestinal irritation and bleeding, as well as kidney-related adverse effects.
  • Diabetes Medications: Salfen may interact with certain medications used to treat diabetes, which could potentially result in dangerously low blood sugar levels (hypoglycemia) and require close monitoring.
  • Digoxin: The absorption of digoxin, a medication used for certain heart conditions, may be reduced when taken concurrently with Salfen, leading to decreased effectiveness of the heart medication.
  • Folic Acid Supplements: Salfen may interfere with the body's normal absorption and use of folic acid (Vitamin B9), potentially leading to a deficiency that requires dietary adjustment or supplementation.

It is essential to inform a healthcare provider or pharmacist about all prescription drugs, over-the-counter medicines, herbal products, and dietary supplements currently being used. This includes any products containing acetaminophen, blood pressure medications, or drugs that affect the kidneys. Alcohol consumption should also be discussed, as it may increase the risk of certain side effects.

Mechanism of Action

Genomic and Transcriptional Downregulation of Inflammation

Salfen's mechanism is defined by the active ingredient, a synthetic glucocorticoid, which modulates inflammatory pathways across molecular and cellular levels by acting as an agonist of the intracellular Glucocorticoid Receptor ( GR). This binding forms a complex that translocates to the nucleus and alters the cell's genetic programming. The complex utilizes transrepression to switch off the synthesis of key pro-inflammatory mediators (like cytokines) and transactivation to synthesize anti-inflammatory proteins, resulting in a substantial downregulation of the cellular capacity to generate inflammatory mediators.

Upstream Blockade of the Arachidonic Acid Cascade

The drug's mechanism effectively halts the entire inflammatory cascade at an early stage by promoting the protein Lipocortin (Annexin A1). Lipocortin indirectly inhibits the enzyme Phospholipase A2 ( PLA2), preventing the release of arachidonic acid—the precursor needed to produce major inflammatory signaling molecules like prostaglandins and leukotrienes. This prevents increased vascular permeability and the chemotaxis of immune cells, leading to a functional reduction in fluid leakage and cellular infiltration within the tissue.

Dosage and Administration Information

How to Use Salfen — Administration Guidelines

Salfen (representing mesalamine/sulfasalazine derivatives) is administered to ensure proper drug delivery and effectiveness. This medication is available for Oral and Rectal administration.

Administration Method and Conditions

Administration Scope Instruction Summary
Route of Administration Oral (tablets, capsules, granules) and Rectal (suppositories, enema).
Preparation and Handling Delayed-release tablets and prolonged-release granules must be swallowed whole. Do not cut, break, crush, or chew the formulation. Granules can be placed on the tongue and swallowed with plenty of liquid.
Timing in Relation to Meals Take oral formulations with or without food, as specified by the product's individual instructions (some extended-release versions may require food for proper absorption).

Dosing and Scheduling

Dosing is based on the specific condition and the patient's age and weight:

  • Adult Dosing: For acute treatment, the total daily dosage generally ranges from 1.5 g to 4.8 g, often split into two to four divided doses daily, or sometimes taken as a single dose for certain once-daily formulations. The maintenance dosage is typically lower, such as 1.6 g to 2.4 g daily, often prescribed as a once-daily regimen to aid consistency.
  • Pediatric Dosing: For children 6 years and older, the dosage is weight-based, calculated in milligrams per kilogram per day (mg/kg/day), up to a maximum adult dose. The total dose is typically divided and taken twice daily.
  • Fluids: Patients should drink an adequate amount of fluids during treatment with Salfen.

Procedural Summary

Standard procedural steps include: swallow the tablet or capsule whole with water, do not chew any prolonged-release form, and take the correct dosage at the prescribed frequency (e.g., three times daily or once daily). If a dose is missed, take the next scheduled dose at the regular time; do not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Salfen

The clinical evaluation of Salfen (prednisolone acetate ophthalmic suspension) is based on scientific research, including controlled trials, which help regulatory bodies understand the findings from studies involving specific types of inflammation in the eye. This overview describes the structure of the evidence without providing clinical advice or making claims about individual outcomes.


Evidence for use in Post-Surgical Ocular Inflammation

Research examining Salfen’s use after eye surgery, such as cataract extraction, has primarily involved short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. The trials aimed to monitor the acute physiological changes during the period following surgery. Studies focused on outcomes linked to inflammatory or irritative states, such as anterior chamber (AC) cell and flare counts (markers of inflammation) and measurements of visual acuity.

What remains uncertain is the long-term status of patients. Follow-up durations were limited, meaning there is limited information for long-term outcomes or tracking the durability of the response beyond the immediate post-surgical period (usually 4–6 weeks).


Evidence for use in Endogenous Anterior Uveitis (Iritis and Iridocyclitis)

Salfen was evaluated in clinical trials for endogenous anterior uveitis. The research explored how patient-reported outcomes describing perceived discomfort were measured. The studies were often structured as comparative trials, meaning research examined Salfen against other active steroid eye drops. Primary outcomes focused on the percentage of patients whose measured inflammatory cell counts were at or below a predetermined threshold in the anterior chamber.

A key point is that the primary data often relies on comparisons with other active treatments, which means the comparative evidence is lacking against a placebo control. The highly controlled trial settings may not perfectly reflect the patterns observed in day-to-day clinical use.


Key Limitations and Areas of Uncertainty

The research landscape for Salfen is generally well-established for the acute anti-inflammatory context in which it was studied. However, key limitations remain, including the lack of comparative evidence against placebo in some core indications. Additionally, the follow-up durations were limited in most controlled trials, meaning the long-term effects are not fully established. There is also variability across studies regarding the exact use and relevance of adding the medicine to treat certain infectious keratitis cases.

Frequently Asked Questions (FAQ)

Common questions about Salfen (FAQ)


Q: How long does it typically take to feel the effects of Salfen?

The official product information states that Salfen works to inhibit the acute inflammatory response. The label advises that if signs and symptoms of the condition do not show improvement after the initial two days of use, the patient should be reevaluated.


Q: Can people with high blood pressure use Salfen?

While the topical ophthalmic suspension is expected to have low absorption into the body, systemic corticosteroids (the drug class Salfen belongs to) have been associated with changes in blood pressure. The drug class information states that monitoring may be necessary for individuals with pre-existing high blood pressure (hypertension).


Q: Is Salfen a branded medicine or is a generic version available?

Salfen is the brand name for a medicine whose active ingredient is Prednisolone Acetate. Yes, the active ingredient in Salfen is Prednisolone Acetate Ophthalmic Suspension, and a generic version of this formulation is approved and available on the market.


Q: Can Salfen affect the results of a blood test?

The drug class to which Salfen belongs (corticosteroids) is known in its systemic form to potentially affect results for blood sugar and electrolyte tests. While the topical eye drop has low systemic absorption, official guidance typically suggests disclosing all medications being used to the laboratory or healthcare provider before blood tests are conducted.


Q: Do older adults typically use a different form of Salfen?

Official prescribing information indicates that no overall differences in the effectiveness or safety profile of the ophthalmic suspension have been specifically identified between older (geriatric) and younger patient populations.


Q: Can Salfen cause changes in mood or anxiety?

Behavioral and mood changes, such as anxiety, depression, and nervousness, have been reported as side effects of the corticosteroid class, especially when the medicine is absorbed systemically. These potential effects are known to be associated with the drug class.


Q: Does Salfen cause weight gain or loss?

Official documents describe that weight gain is a known effect of the corticosteroid drug class, often due to fluid retention. While the topical eye suspension has limited absorption into the body, this is an effect described as associated with the medicine's drug class.


Q: What happens when I stop using Salfen?

The labeling advises against premature discontinuation. For long-term use, the official documentation describes a process of gradual reduction in application frequency to avoid potential rebound inflammation. This gradual approach is intended to allow the body to adjust.


Q: Does Salfen have a Black Box Warning?

According to the US FDA prescribing information, Prednisolone Acetate Ophthalmic Suspension does not carry a specific Black Box Warning (also called a Boxed Warning) in the Highlights section.


Q: Why is it described that Salfen 'supports' rather than 'cures' a condition?

The action of Salfen is to rapidly control the physical signs of inflammation, such as swelling and redness, by inhibiting key cellular processes. Its function is described as the comprehensive suppression of the inflammatory response, which helps manage symptoms rather than eliminating the underlying cause of the disease.


Q: Are there any common foods or drinks to avoid while using Salfen?

There are no specific foods officially prohibited when using the ophthalmic suspension. However, the systemic use of this drug class may interact with compounds like grapefruit juice. Official regulatory information highlights the need to discuss alcohol consumption with a healthcare provider due to the potential to increase certain side effects.


Q: Does Salfen interact with common over-the-counter cold medicines?

The medicine's regulatory information notes potential interactions with certain drugs, including NSAIDs (non-steroidal anti-inflammatory drugs), which are often found in cold and pain relief products. Combining these types of medicines may increase the risk of side effects. Official information typically recommends that patients disclose all over-the-counter products to their healthcare provider.


Q: Can Salfen interact with natural health products like herbal teas?

Official drug labeling often lacks specific information about interactions with herbal or natural health products because these items are not tested in the same way as prescription drugs. Regulatory guidance includes a cautionary statement about discussing all herbal products, supplements, and teas with a healthcare provider.


Q: Is Salfen used to treat acute or chronic conditions?

Salfen is indicated for inflammatory conditions that respond to corticosteroids. Regulatory instructions outline a potentially more frequent administration for the initial acute phase (first 24 to 48 hours). For follow-up or chronic conditions, the official guidelines describe a gradual reduction in application frequency. The presence of these distinct regimens suggests its use may include both initial and chronic management contexts.


Q: Is Salfen approved in countries outside the US?

Yes, the active ingredient, Prednisolone Acetate Ophthalmic Suspension, is approved and regulated by various health authorities outside of the US, including official bodies in the UK and member states of the European Union.

How should Salfen be stored and disposed of?

Storage Requirements

Salfen (prednisolone acetate ophthalmic suspension) must be stored at Controlled Room Temperature, typically 15 C to 25 C (59 F to 77 F). It is a mandatory requirement to protect the product from freezing and excessive light. The container must be kept tightly closed and stored in an upright position.

Stability and Child Safety

To ensure proper stability and dose consistency of the suspension, the bottle must be shaken well before using. Following the initial opening, the product must be discarded after 28 days, even if some medication remains. This medicine must be kept out of the sight and reach of children at all times.

Official Disposal Rules

Unused or expired Salfen must not be thrown away with household waste or disposed of in wastewater. The official recommendation is to return the unwanted medicine to a pharmacist or a local collection point for safe and environmentally responsible disposal, adhering to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salfen found in:

A-Z Index: